SCHEMBL5886396

SCHEMBL5886396

COC(=O)C(CN(C)C)NC(=O)c1cccc2nc3ccc4c(OC)cccc4c3nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 5/20 0.47
SMARCA2 P51531 1/20 0.47
TACR3 P29371 5/20 0.40
UHRF1 Q96T88 1/20 0.39
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 2/20 0.36
MAPT P10636 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
TACR2 P21452 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
NFKB1 P19838 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886288 0.93 RAD52 (0.47) RAD52SMARCA2TACR3UHRF1TAS1R3
SCHEMBL23583616 0.89 RAD52 (0.48) RAD52SMARCA2TACR3UHRF1TAS1R3
SCHEMBL29406105 0.89 RAD52 (0.48) RAD52SMARCA2TACR3UHRF1TAS1R3
SCHEMBL5886260 0.77 KMT2A (0.51) RAD52SMARCA2KMT2AMEN1POLB
SCHEMBL5886271 0.76 ALDH1A1 (0.54) RAD52SMARCA2KMT2AMEN1POLB
SCHEMBL5886339 0.76 RAD52 (0.45) RAD52SMARCA2UHRF1KMT2AMEN1
SCHEMBL7066812 0.76 RAD52 (0.39) RAD52SMARCA2TACR3UHRF1TAS1R3
SCHEMBL26843514 0.75 RAD52 (0.45) RAD52SMARCA2TACR3KMT2AMEN1
SCHEMBL5886580 0.74 RAD52 (0.57) RAD52SMARCA2UHRF1MAPTKDM4E
SCHEMBL7066262 0.74 TAS1R3 (0.36) RAD52SMARCA2TACR3UHRF1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A RAD52 2083/4885SMARCA2 1543/4885TACR3 256/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B RAD52 60/4885SMARCA2 1456/4885TACR3 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.